Patents by Inventor Jeff PIOTROWSKI

Jeff PIOTROWSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11873298
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: January 16, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
  • Publication number: 20220110920
    Abstract: The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Inventors: Rebecca ARON, Bhaumik PANDYA, Daniel TARDIFF, Jeff PIOTROWSKI, Matthew LUCAS, Bertrand LE BOURDONNEC, Kenneth RHODES, Robert SCANNEVIN
  • Patent number: 11241417
    Abstract: The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: February 8, 2022
    Assignee: Yumanity Therapeutics, Inc.
    Inventors: Rebecca Aron, Bhaumik Pandya, Daniel Tardiff, Jeff Piotrowski, Matthew Lucas, Bertrand Le Bourdonnec, Kenneth Rhodes, Robert Scannevin
  • Patent number: 10973810
    Abstract: The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 13, 2021
    Assignee: Yumanity Therapeutics, Inc.
    Inventors: Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Bertrand Le Bourdonnec, Matthew Lucas, Kenneth Rhodes
  • Publication number: 20200262828
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 20, 2020
    Inventors: Matthew LUCAS, Bertrand LE BOURDONNEC, Iwona WRONA, Bhaumik PANDYA, Parcharee TIVITMAHAISOON, Kerem OZBOYA, Benjamin VINCENT, Daniel TARDIFF, Jeff PIOTROWSKI, Eric SOLIS, Robert SCANNEVIN, Chee-Yeun CHUNG, Rebecca ARON, Kenneth RHODES
  • Publication number: 20200010462
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: October 24, 2017
    Publication date: January 9, 2020
    Inventors: Matthew LUCAS, Bertrand LE BOURDONNEC, Iwona WRONA, Bhaumik PANDYA, Parcharee TIVITMAHAISOON, Kerem OZBOYA, Benjamin VINCENT, Daniel TARDIFF, Jeff PIOTROWSKI, Eric SOLIS, Robert SCANNEVIN, Chee-Yeun CHUNG, Rebecca ARON, Kenneth Rhodes
  • Publication number: 20190388397
    Abstract: The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression.
    Type: Application
    Filed: June 21, 2019
    Publication date: December 26, 2019
    Inventors: Rebecca ARON, Bhaumik PANDYA, Daniel TARDIFF, Jeff PIOTROWSKI, Matthew LUCAS, Bertrand LE BOURDONNEC, Kenneth RHODES, Robert SCANNEVIN
  • Publication number: 20180193325
    Abstract: The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: January 5, 2018
    Publication date: July 12, 2018
    Inventors: Benjamin VINCENT, Daniel TARDIFF, Jeff PIOTROWSKI, Eric SOLIS, Robert SCANNEVIN, Chee-Yeun CHUNG, Rebecca ARON, Bertrand LE BOURDONNEC, Matthew LUCAS, Kenneth RHODES